Breaking News Instant updates and real-time market news.

MYL

Mylan

$36.49

-1.39 (-3.67%)

11:49
10/17/16
10/17
11:49
10/17/16
11:49

Blumenthal urges DOJ to reject Mylan EpiPen settlement, WFSB reports

Senator Richard Blumenthal is urging the U.S. Department of Justice to reject a proposed settlement with Mylan over a misclassification of EpiPens, stating that the pact is a "shadow of what it should be - lacking real accountability for Mylan's apparent lawbreaking," according to WFSB. Reference Link

  • 09

    Nov

  • 28

    Mar

MYL Mylan
$36.49

-1.39 (-3.67%)

10/10/16
RAJA
10/10/16
UPGRADE
Target $57
RAJA
Strong Buy
Mylan upgraded to Strong Buy on EpiPen settlement at Raymond James
As previously reported, Raymond James upgraded Mylan two notches to Strong Buy from Market Perform and established a $57 price target. Analyst Elliot WIlbur said the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. With depressed absolute and relative valuation levels, Wilber sees favorable risk/reward scenarios even in a more tempered earnings growth environment.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan settlement, updated guidance a positive, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's $465M settlement with the Department of Justice relating to the potential misclassification of Epipen in the Medicaid Drug Rebate Program as well as its updated 2016 guidance as a positive. The news "removes litigation overhang at a reasonable cost and highlights the diversification of the base business and inexpensive valuation," Schott tells investors in a research note. He keeps an Overweight rating on Mylan with a $52 price target.
10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/10/16
10/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

08:25
09/21/17
09/21
08:25
09/21/17
08:25
General news
N.Y. FX Outlook »

N.Y. FX Outlook:…

BCRX

BioCryst

$5.27

-0.16 (-2.95%)

08:22
09/21/17
09/21
08:22
09/21/17
08:22
Technical Analysis
Technical View: BioCryst up on FDA news concerning Rapivab »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

MU

Micron

$35.97

0.02 (0.06%)

08:22
09/21/17
09/21
08:22
09/21/17
08:22
Recommendations
Micron analyst commentary  »

Micron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

$DJT

DJ Transportation Average

08:21
09/21/17
09/21
08:21
09/21/17
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETR

Entergy

$77.80

-0.25 (-0.32%)

08:21
09/21/17
09/21
08:21
09/21/17
08:21
Upgrade
Entergy rating change  »

Entergy upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 05

    Nov

$DJU

DJ Utility Average

08:21
09/21/17
09/21
08:21
09/21/17
08:21
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:21
09/21/17
09/21
08:21
09/21/17
08:21
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UFI

Unifi

$32.91

0.09 (0.27%)

08:21
09/21/17
09/21
08:21
09/21/17
08:21
Conference/Events
Unifi management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

IYT

iShares Transportation Average

$174.15

2.54 (1.48%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$58.81

-0.24 (-0.41%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$66.84

0.45 (0.68%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPCN

Lipocine

$4.00

0.07 (1.78%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20
Hot Stocks
Lipocine announces motions decision by USPTO »

Lipocine announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

08:20
09/21/17
09/21
08:20
09/21/17
08:20
General news
U.S. initial jobless claims preview: »

U.S. initial jobless…

XLY

Consumer Discretionary Sector SPDR

$89.54

0.3 (0.34%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$56.87

0.2 (0.35%)

08:19
09/21/17
09/21
08:19
09/21/17
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$53.68

-0.4 (-0.74%)

08:19
09/21/17
09/21
08:19
09/21/17
08:19
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$54.60

-0.53 (-0.96%)

08:19
09/21/17
09/21
08:19
09/21/17
08:19
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HKMPY

Hikma

08:18
09/21/17
09/21
08:18
09/21/17
08:18
Conference/Events
Hikma has a conference call hosted by JPMorgan »

JPMorgan Analyst Gordon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

XLV

Health Care Select Sector SPDR

$82.00

0.08 (0.10%)

08:18
09/21/17
09/21
08:18
09/21/17
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:18
09/21/17
09/21
08:18
09/21/17
08:18
Conference/Events
Cowen to hold a tour »

Vehicles, Vision &…

SUP

Superior Industries

$16.00

0.45 (2.89%)

08:18
09/21/17
09/21
08:18
09/21/17
08:18
Conference/Events
Superior Industries management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

  • 30

    Oct

IWM

iShares Trust Russell 2000 Index Fund

$143.84

0.46 (0.32%)

08:18
09/21/17
09/21
08:18
09/21/17
08:18
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$223.90

0.32 (0.14%)

08:18
09/21/17
09/21
08:18
09/21/17
08:18
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$113.84

38.8 (51.71%)

08:18
09/21/17
09/21
08:18
09/21/17
08:18
Recommendations
Alnylam analyst commentary  »

Alnylam price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$250.06

0.09 (0.04%)

08:17
09/21/17
09/21
08:17
09/21/17
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.